Clinical effect of osimertinib combined with concurrent chemoradiotherapy in the treatment of patients with advanced non-small cell lung cancer with EGFR T790M mutation
Objective To investigate the clinical effect of osimertinib combined with concurrent chemoradiotherapy in the treatment of patients with advanced non-small cell lung cancer(NSCLC)with epidermal growth factor receptor(EGFR)T790M mutation.Methods A total of 82 patients with advanced NSCLC with EGFR T790M mutation admitted in our hospital from March 2016 to September 2018 were selected and divided into control group(41 cases)and observation group(41 cases)by random number table method.The control group was treated with concurrent chemoradiotherapy,and the observation group was treated with osimertinib combined with concurrent chemoradiotherapy.The therapeutic effects of the two groups were compared.Results The disease control rate and objective remission rate of the observation group were higher than those of the control group,and the differences were statistically significant(P<0.05).The incidences of gradeⅠ+Ⅱrash,gastrointestinal reaction and paronychia in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After 2 years of follow-up,the progression free survival(PFS)of the observation group was 11.32(6.85,12.41)months,which was longer than 7.29(4.91,9.32)months of the control group(P<0.05);after 1 and 2 years of follow-up,the survival rates of the observation group were 75.61%and 39.02%,which were higher than 56.10%and 12.20%of the control group,and the differences were statistically significant(P<0.05).Conclusion Osimertinib combined with concurrent chemoradiotherapy in the treatment of advanced NSCLC patients with EGFR T790M mutation can improve the short-term and long-term therapeutic effect,prolong PFS and improve the survival rate of patients,it has higher clinical application value.
osimertinibconcurrent chemoradiotherapyepidermal growth factor receptorT790M mutationnon-small cell lung cancer
万方数据
维普
